In Brief: U.S./EU device MRA
This article was originally published in The Gray Sheet
Executive Summary
U.S./EU device MRA: April 25 teleconference between U.S. and European Union negotiators on a medical device mutual recognition agreement outlines remaining work to be done but produces no substantial headway on key issues of product coverage and identification of notified bodies, FDA staffers say. The next teleconference is set for May 5, with agency seeking possible face-to-face meetings in Washington or Brussels during the weeks of May 12 or May 19. An April 19 letter from EU President Jaques Santer to President Clinton places additional pressure to complete negotiations before a May 28 Summit meeting in The Hague, The Netherlands. That correspondence urges Clinton to take "personal intervention" in the MRA negotiations and notes that in medical devices and drugs, "the product coverage proposed by the U.S. side is far too limited and the commitment to recognize the results of our assessments too lose"...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.